161 related articles for article (PubMed ID: 28420659)
1. Very low expression of PD-L1 in medullary thyroid carcinoma.
Bongiovanni M; Rebecchini C; Saglietti C; Bulliard JL; Marino L; de Leval L; Sykiotis GP
Endocr Relat Cancer; 2017 Jun; 24(6):L35-L38. PubMed ID: 28420659
[No Abstract] [Full Text] [Related]
2. PD-1/PD-L1 expressions in medullary thyroid carcinoma: Clinicopathologic and prognostic analysis of Chinese population.
Bi Y; Ren X; Bai X; Meng Y; Luo Y; Cao J; Zhang Y; Liang Z
Eur J Surg Oncol; 2019 Mar; 45(3):353-358. PubMed ID: 30528043
[TBL] [Abstract][Full Text] [Related]
3. A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer.
Del Rivero J; Donahue RN; Marté JL; Gramza AW; Bilusic M; Rauckhorst M; Cordes L; Merino MJ; Dahut WL; Schlom J; Gulley JL; Madan RA
Front Endocrinol (Lausanne); 2020; 11():490. PubMed ID: 32849281
[TBL] [Abstract][Full Text] [Related]
4. CD70 and PD-L1 in anaplastic thyroid cancer - promising targets for immunotherapy.
Zwaenepoel K; Jacobs J; De Meulenaere A; Silence K; Smits E; Siozopoulou V; Hauben E; Rolfo C; Rottey S; Pauwels P
Histopathology; 2017 Sep; 71(3):357-365. PubMed ID: 28383817
[TBL] [Abstract][Full Text] [Related]
5. Expression of PD-L1 in medullary thyroid carcinoma-a new therapeutic target?
Fonseca L; Freitas C; Caramelo A; Eloy C
Endocrinol Diabetes Metab; 2021 Jul; 4(3):e00241. PubMed ID: 34277966
[TBL] [Abstract][Full Text] [Related]
6. Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial.
Bodet-Milin C; Faivre-Chauvet A; Carlier T; Rauscher A; Bourgeois M; Cerato E; Rohmer V; Couturier O; Drui D; Goldenberg DM; Sharkey RM; Barbet J; Kraeber-Bodere F
J Nucl Med; 2016 Oct; 57(10):1505-1511. PubMed ID: 27230928
[TBL] [Abstract][Full Text] [Related]
7. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.
Brauner E; Gunda V; Vanden Borre P; Zurakowski D; Kim YS; Dennett KV; Amin S; Freeman GJ; Parangi S
Oncotarget; 2016 Mar; 7(13):17194-211. PubMed ID: 26943572
[TBL] [Abstract][Full Text] [Related]
8. Heat shock proteins HSP90, HSP70 and GRP78 expression in medullary thyroid carcinoma.
Soudry E; Stern Shavit S; Hardy B; Morgenstern S; Hadar T; Feinmesser R
Ann Diagn Pathol; 2017 Feb; 26():52-56. PubMed ID: 28038712
[TBL] [Abstract][Full Text] [Related]
9. Immune Profiling of Medullary Thyroid Cancer-An Opportunity for Immunotherapy.
Hińcza-Nowak K; Kowalik A; Walczyk A; Pałyga I; Gąsior-Perczak D; Płusa A; Kopczyński J; Chrapek M; Góźdź S; Kowalska A
Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680929
[TBL] [Abstract][Full Text] [Related]
10. Analytical Performance of a Gene Expression Classifier for Medullary Thyroid Carcinoma.
Pankratz DG; Hu Z; Kim SY; Monroe RJ; Wong MG; Traweek ST; Kloos RT; Walsh PS; Kennedy GC
Thyroid; 2016 Nov; 26(11):1573-1580. PubMed ID: 27605259
[TBL] [Abstract][Full Text] [Related]
11. A novel CCK2/gastrin receptor-localizing radiolabeled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma: a multicenter phase I GRAN-T-MTC study.
Erba PA; Maecke H; Mikolajczak R; Decristoforo C; Zaletel K; Maina-Nock T; Peitl PK; Garnuszek P; Froberg A; Goebel G; de Jong M; Jabrocka-Hybel A; Konijnenberg M; Virgolini I; Nock B; Lenda-Tracz W; Pawlak D; Rangger C; Trofimiuk-Müldner M; Sowa-Staszczak A; Tomaszuk M; von Guggenberg E; Scarpa L; Hubalewska-Dydejczyk A
Pol Arch Intern Med; 2018 Dec; 128(12):791-795. PubMed ID: 30516761
[No Abstract] [Full Text] [Related]
12. The pathogenesis and treatment differences between differentiated thyroid carcinoma and medullary thyroid carcinoma.
Su J; Fu Y; Wang M; Yan J; Lin S
Curr Med Res Opin; 2022 Oct; 38(10):1769-1770. PubMed ID: 35621192
[No Abstract] [Full Text] [Related]
13. Consensus on management of advanced medullary thyroid carcinoma on behalf of the Working Group of Thyroid Cancer of the Spanish Society of Endocrinology (SEEN) and the Spanish Task Force Group for Orphan and Infrequent Tumors (GETHI).
Grande E; Santamaría Sandi J; Capdevila J; Navarro González E; Zafón Llopis C; Ramón Y Cajal Asensio T; Gómez Sáez JM; Jiménez-Fonseca P; Riesco-Eizaguirre G; Galofré JC
Clin Transl Oncol; 2016 Aug; 18(8):769-75. PubMed ID: 26687366
[TBL] [Abstract][Full Text] [Related]
14. Aberrant expression of tumor-associated carbohydrate antigen Globo H in thyroid carcinoma.
Cheng SP; Yang PS; Chien MN; Chen MJ; Lee JJ; Liu CL
J Surg Oncol; 2016 Dec; 114(7):853-858. PubMed ID: 27753098
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors.
Wang H; Li Z; Dong B; Sun W; Yang X; Liu R; Zhou L; Huang X; Jia L; Lin D
Diagn Pathol; 2018 May; 13(1):30. PubMed ID: 29789013
[TBL] [Abstract][Full Text] [Related]
16. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.
Sundara YT; Kostine M; Cleven AH; Bovée JV; Schilham MW; Cleton-Jansen AM
Cancer Immunol Immunother; 2017 Jan; 66(1):119-128. PubMed ID: 27853827
[TBL] [Abstract][Full Text] [Related]
17. Medullary thyroid carcinoma with extremely rare presentation in a child: Considerations for management.
Moreddu E; Guerin C; Nicollas R; Aschero A; Essamet W; Min V; Coze C
Pediatr Blood Cancer; 2024 Mar; 71(3):e30823. PubMed ID: 38189596
[No Abstract] [Full Text] [Related]
18. PD-L1 Expression in Lung Cancer.
Yu H; Boyle TA; Zhou C; Rimm DL; Hirsch FR
J Thorac Oncol; 2016 Jul; 11(7):964-75. PubMed ID: 27117833
[TBL] [Abstract][Full Text] [Related]
19. [Postoperative external beam radiotherapy for medullary thyroid carcinoma with high risk of locoregional relapse].
Compagnon F; Zerdoud S; Rives M; Laprie A; Sarini J; Grunenwald S; Chaltiel L; Graff P
Cancer Radiother; 2016 Jul; 20(5):362-9. PubMed ID: 27396902
[TBL] [Abstract][Full Text] [Related]
20. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.
Lafuente-Sanchis A; Zúñiga Á; Estors M; Martínez-Hernández NJ; Cremades A; Cuenca M; Galbis JM
Clin Lung Cancer; 2017 Mar; 18(2):e109-e116. PubMed ID: 27816393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
